Press Centre
Press Releases
Disclosure of information required by AIM Rule 26
Phynova Group plc
("Company")
Disclosure of information required by AIM Rule 26
Phynova Group plc (AIM: PYN), the developer of prescription pharmaceuticals derived from Chinese botanical medicines, announces that the information required by Rule 26 of the AIM Rules for Companies (February 2007) is available under the heading "AIM Rule 26" within the "Investors" section of the Company´s website www.phynova.com.
- Ends -
For further information, please contact:
Phynova Group plc +44 (0) 1993 880700
Alan Brown, Finance Director www.phynova.com
Nominated Adviser:
Nabarro Wells & Co. Limited +44 (0) 20 7710 7400
Marc Cramsie/John Wilkes
Broker:
Evolution Securities China Limited +44 (0) 20 7220 4878
Barry Saint
Media enquiries:
Abchurch Communications +44 (0) 20 7398 7711
Ashley Tapp
ashley.tapp@abchurch-group.com
www.abchurch-group.com
Notes to Editors:
About Phynova
Phynova is a UK company developing prescription pharmaceuticals derived from Chinese botanical medicines. Phynova is focused on viral and metabolic diseases and cancer. Phynova´s lead product for hepatitis C is now in a Phase IIa trial in the US. Two further products, for fatty liver disease and post-operative ileus, are targeted for entry to the clinic in early 2008 and there are a further three products in preclinical development.
About Hepatitis C and Phynova´s clinical candidate PYN17
Hepatitis C is a liver disease caused by the hepatitis C virus ("HCV"). Hepatitis C is usually transmitted by injections of illicit drugs, or through exposure to contaminated blood or blood products. Symptoms include fatigue, abdominal discomfort or tenderness, muscle and joint pain, nausea and loss of appetite. Symptoms may persist in patients, even after viral clearance following interferon-ribavirin therapy. Chronic hepatitis C can result in cirrhosis of the liver, which can lead to liver failure and other serious complications, and liver cancer.
Hepatitis C affects over 170 million people world wide, including over four million people in the US. Currently available treatments with pegylated interferon and ribavirin are only effective in approximately 50% of patients treated, often with significant associated toxicity and side effects. The market for treatments for hepatitis C is estimated to be US$9 billion by 2010.
Phynova believes that PYN17 is the only drug in clinical development specifically designed to treat the debilitating symptoms of chronic hepatitis C. It is based on a novel formulation of four plant extracts that have a long history of safe and efficacious use in the treatment of liver ailments in Asia and the West.
For further information please visit www.phynova.com
13/08/2007
<< Back | See all current Press releses